Scarica l'app Stockscreener
56.83
1.05%
0.59
Dopo l'orario di chiusura:
56.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$56.24
Aprire:
$56.41
Volume 24 ore:
426.37K
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.64B
Reddito:
$1.32B
Utile/perdita netta:
$175.44M
Rapporto P/E:
15.61
EPS:
3.6395
Flusso di cassa netto:
$308.08M
1 W Prestazione:
+2.36%
1M Prestazione:
-11.04%
6M Prestazione:
+16.22%
1 anno Prestazione:
-11.26%
Intervallo 1D:
$55.30
$57.33
Intervallo di 1 settimana:
$53.88
$57.33
Portata 52W:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
56.83 | 2.64B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | Needham | Buy → Hold |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE - MarketBeat
HAE PE Ratio & Valuation, Is HAE Overvalued - intellectia.ai
Haemonetics Corporation (HAE) Stock forecasts - Yahoo Finance UK
Haemonetics will post earnings at 6 a.m., then take questions at 8 - Stock Titan
Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE - MarketBeat
Avantis U.S. Small Cap Equity Fund's Haemonetics Corp(HAE) Holding History - GuruFocus
Automatic Blood Bag Tube Stripper Market Is Going to Boom | Terumo - openPR.com
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $88 - 富途牛牛
Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27 - TipRanks
Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system - TipRanks
FDA Expands Approval for Haemonetics' (HAE) VASCADE MVP XL Syste - GuruFocus
Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat? - simplywall.st
Haemonetics wins FDA nod for expanded vascular closure system use - Investing.com
Haemonetics Wins FDA Approval to Expand Label for VASCADE MVP XL - marketscreener.com
FDA expands use of Haemonetics device in atrial fibrillation care - Stock Titan
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Haemonetics stock maintained at Buy by BTIG on FDA label expansion - Investing.com South Africa
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE - MarketBeat
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7% - MarketBeat
Vanguard disaggregates holdings after internal realignment (NYSE: HAE) - Stock Titan
Update Recap: What drives Haemonetics Corporations stock price2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Q2 EPS Estimates for Haemonetics Boosted by Zacks Research - MarketBeat
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Q3 EPS Estimates for Haemonetics Increased by Zacks Research - MarketBeat
HAE Price Today: Haemonetics Corporation Stock Price, Quote & Chart - MEXC Exchange
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector - AD HOC NEWS
Why Haemonetics Stock Is Suddenly Bouncing Back - TipRanks
Hospital Solutions launch from Haemonetics aims to transform patient care standards - Traders Union
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand - AD HOC NEWS
Don't Get Too Worked Up Over Haemonetics's Earnings - Yahoo
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year - AOL.com
Haemonetics Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Haemonetics Corporation (HAE) Q3 performance prompts Baird model update, price target falls to $81 - MSN
London Co. of Virginia Decreases Stake in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Haemonetics Corporation $HAE Shares Purchased by Invenomic Capital Management LP - MarketBeat
Haemonetics Corp Stock (ISIN: US4041191090) Faces Pressure Amid Hospital Recovery and Debt Concerns - AD HOC NEWS
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Haemonetics (HAE) Quietly Rewiring Its Margin Profile Through NexSys PCS And Hospital Acquisitions? - simplywall.st
Does Haemonetics' (HAE) Hospital Rebound and NexSys Expansion Reframe Its Competitive Positioning? - Yahoo Finance
Aristotle Capital Boston LLC Increases Stock Position in Haemonetics Corporation $HAE - MarketBeat
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $70 - 富途牛牛
Haemonetics Corp Stock (ISIN: US4041191090) Expands Hospital Portfolio Amid Valuation Discount and A - AD HOC NEWS
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $70 - 富途牛牛
Haemonetics Expands Hospital Portfolio As Investors Weigh Growth And Valuation - simplywall.st
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics - Markets Mojo
Haemonetics Corporation $HAE Shares Sold by Schroder Investment Management Group - MarketBeat
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):